Navigation Links
Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing

MONTVALE, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announces results of a clinical trial known as the ICARE study, being presented today at the American Heart Association's (AHA) Scientific Sessions 2007 in Orlando, Florida. The study demonstrated that supplementing Vitamin E therapy in patients with Diabetes Mellitus (DM) who had the Haptoglobin 2-2 (Hp2-2) phenotype met its pre-specified, primary endpoint of decreased cardiovascular events, leading to early termination of the four-year study after just 18 months.

"We are thrilled that Dr. Andrew P. Levy and his colleagues at the Rappaport Research Institute in the Technion Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel, and Clalit Health Services, Haifa and Western Galilee, Israel conducted this study to evaluate the efficacy of treating Hp2-2, DM patients with Vitamin E," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista. "Vitamin E has been the subject of significant controversy in recent years, with several meta-analyses showing increased mortality for patients treated with this nutraceutical. We find it validating to identify the possibility, in a large, prospective clinical trial, that patients can test their Haptoglobin type and then receive an inexpensive therapy that has demonstrated clinical benefit. This is targeted therapy at its best. Further, we believe this study provides scientific rationale for our current development platform, which is based on targeting our oxidized lipid reducing product candidate, ALT-2074, to patients with DM who test positive for Hp2-2 with our diagnostic technology for Haptoglobin."

In the placebo-controlled ICARE study, more than 3,000 patients were tested for Haptoglobin phenotype, and 984 of these who had the Hp2-2 phenotype were randomized to receive either natural source Vitamin E (400 IU daily) or placebo. Primary endpoints of the study were non-fatal myocardial infarction (MI--heart attack), stroke and cardiovascular death. Results demonstrated a greater than 50% decrease in cardiovascular events in patients receiving Vitamin E (1.0 percent compared to 3.8 percent, p=0.004), leading to early termination of the study. Investigators determined this result to be predominantly due to a significant decrease in non-fatal myocardial infarction in the Vitamin E group.

"Our research group has postulated that the profoundly increased risk of, MI, stroke and cardiovascular death observed in DM patients with Hp2-2, established in many observational studies of more than 20,000 patients in recent years, may be a consequence of a defect in the antioxidant protection of Hp2-2," added Dr. Levy. "As a member of my group, Dr. Rabea Asleh, reported earlier today, this defect may interfere with reverse cholesterol transport. This in turn may promote a more inflamed and labile atherosclerotic plaque. It is gratifying to have had this opportunity to collaborate with Clalit Health Services, the largest health plan in Israel, in a large prospective clinical trial that provides strong support for the claim that Vitamin E can be targeted to DM patients with Hp2-2 and provide a significant clinical benefit."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... Nov. 26, 2015  The total global healthcare industry is ... 2015-2016. Latin America has the highest ... (excluding Japan ), is second with growth ... to face increased healthcare expenditure. In 2013-2014, total government funded ... 43.5% in 2008-2009 to 41.2% in 2013-2014. In real terms, ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of the ... 2016, at Caesars Palace in Las Vegas with a pre-conference session on a ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
(Date:11/26/2015)... Marne, MI (PRWEB) , ... November 26, 2015 ... ... center for substance abuse located in central Michigan, have come together on Thanksgiving ... a specially produced video, available for viewing on the Serenity Point YouTube channel, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and ... offered by healthcare staffing agency Aureus Medical Group . These fields, ... 2015 among those searching for healthcare jobs through the company’s website, ...
Breaking Medicine News(10 mins):